Our cloud-based library of optical fingerprints, powered by photonics and AI, provides non-invasive tracking, screening and stratification for drug discovery, adapted to each clinical trial needs.
Efficient. Flexible. Patient-centric.
Minimally Invasive
Requires only microlitres of blood
Agnostic
Allows for label free flexibility on targets
Rapid
Takes <10 seconds from start to finish
Low cost
Requires no consumables, only Light and AI
How can we help?
Our blood-based screening test stratifies patients for clinical trials, removing heterogeneity due to pathophysiology, disease stage or degree of progression.
The iLoF Platform offers:
40% cost savings
70% reduction of time spent on screenings
A non-invasive process for patient convenience
A pool of more qualified candidates, improving trial outcomes
Paving the way for personalised medicine
One platform, endless posibilities.
With Alzheimer’s as a main focus, we are building out our virtual fingerprint library and bringing the power of our technology to other diseases
COVID-19
Forecasting clinical outcomes and predicting severity of symptoms
Gastric Cancer
Stratifying cancer subtypes allowing for design and delivery of tailored treatments
Stroke
Differentiating between ischemic and hemorrhagic stroke patients for timely clinical management
Investors and Partners
Awards
GET IN TOUCH
United Kingdom
Oxford Foundry – University of Oxford
3-5 Hythe Bridge St
OX1 2EW Oxford
(+44) 01865 679064
Portugal
Medical Research Center
R. Dr. Plácido da Costa
4200-450 Porto
(+351) 220 426 664
info@ilof.tech
